Share on StockTwits

GenMark Diagnostics (NASDAQ:GNMK) CFO Richard B. Slansky unloaded 2,302 shares of the stock in a transaction dated Thursday, May 8th. The shares were sold at an average price of $9.26, for a total transaction of $21,316.52. Following the completion of the transaction, the chief financial officer now directly owns 79,534 shares of the company’s stock, valued at approximately $736,485. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of research firms have recently commented on GNMK. Analysts at Raymond James reiterated an “outperform” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $11.00 price target on the stock, down previously from $14.00. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $16.00 price target on the stock, down previously from $17.00. Finally, analysts at Cowen and Company reiterated an “outperform” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $15.00 price target on the stock, down previously from $16.00. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $15.00.

Shares of GenMark Diagnostics (NASDAQ:GNMK) traded up 2.86% during mid-day trading on Monday, hitting $9.34. 149,504 shares of the company’s stock traded hands. GenMark Diagnostics has a one year low of $8.48 and a one year high of $15.49. The stock has a 50-day moving average of $9.49 and a 200-day moving average of $11.65. The company’s market cap is $388.6 million.

GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.04. The company had revenue of $7.91 million for the quarter, compared to the consensus estimate of $6.40 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. The company’s revenue for the quarter was down 28.7% on a year-over-year basis. Analysts expect that GenMark Diagnostics will post $-1.16 EPS for the current fiscal year.

GenMark Diagnostics, Inc (NASDAQ:GNMK) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.